CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: Implications for prophylaxis and treatment

被引:140
作者
Holmes, Charles B.
Wood, Robin
Badri, Motasim
Zilber, Sophia
Wang, Bingxia
Maartens, Gary
Zheng, Hui
Lu, Zhigang
Freedberg, Kenneth A.
Losina, Elena
机构
[1] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr AIDS Res, Dept Med, Boston, MA 02114 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Univ Cape Town, Desmond Tutu Res Ctr, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa
[6] Univ Cape Town, Dept Clin Pharmacol, ZA-7925 Cape Town, South Africa
[7] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
[8] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA
[9] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA
关键词
HIV; opportunistic infections; CD4 cell count; South Africa; prophylaxis;
D O I
10.1097/01.qai.0000225729.79610.b7
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objectives: To determine the rate of CD4 decline and the incidence of opportunistic infections (OIs) among antiretroviral therapy-naive South African HIV-infected patients and inform timing of OI prophylaxis. Methods: We used mixed-effect models to estimate CD4 cell decline by CD4 cell count strata in HIV-infected patients in the Cape Town AIDS Cohort between 1984 and 2000. Stratum-specific OI incidence per 100 person-years of observation was determined using incidence density analysis. Results: Nine hundred seventy-four patients with 2 or more CD4 cell counts were included. CD4 counts declined by 47.1 cells/mu L per year in the stratum with more than 500 cells/mu L, 30.6 cells/mu L per year in the stratum with 351 to 500 cells/mu L, and 20.5 cells/mu L per year in the stratum with 201 to 350 cells/mu L. Tuberculosis and oral candidiasis were the only OIs that occurred frequently in the stratum with more than 200 CD4 cells/RL. Rates of chronic diarrhea, wasting syndrome, tuberculosis, and oral and esophageal candidiasis increased in the stratum with less than 200 cells/mu L, and rates of all OIs were highest in the stratum with 50 cells/mu L or less. Conclusions: CD4 cell count declines were dependent on CD4 strata and can inform timing of clinic visits and treatment initiation in South Africa. Incidence rates of OIs suggest that targeted OI prophylaxis could prevent substantial HIV-related morbidity in South Africa.
引用
收藏
页码:464 / 469
页数:6
相关论文
共 38 条
[1]   Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire:: a randomised trial [J].
Anglaret, X ;
Chêne, G ;
Attia, A ;
Toure, S ;
Lafont, S ;
Combe, P ;
Manlan, K ;
N'Dri-Yoman, T ;
Salamon, R .
LANCET, 1999, 353 (9163) :1463-1468
[2]  
[Anonymous], 1990, Wkly Epidemiol Rec, V65, P221
[3]  
[Anonymous], 2002, ANAL LONGITUDINAL DA
[4]   Usefulness of total lymphocyte count in monitoring highly active antiretroviral therapy in resource-limited settings [J].
Badri, M ;
Wood, R .
AIDS, 2003, 17 (04) :541-545
[5]  
Badri M, 2002, INT J TUBERC LUNG D, V6, P231
[6]   Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study [J].
Badri, M ;
Wilson, D ;
Wood, R .
LANCET, 2002, 359 (9323) :2059-2064
[7]   Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations [J].
Badri, M ;
Ehrlich, R ;
Wood, R ;
Maartens, G .
AIDS, 2001, 15 (09) :1143-1148
[8]   Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials [J].
Bucher, HC ;
Griffith, LE ;
Guyatt, GH ;
Sudre, P ;
Naef, M ;
Sendi, P ;
Battegay, M .
AIDS, 1999, 13 (04) :501-507
[9]  
*CDCP, 1987, MMWR-MORBID MORTAL W, V36, pS3
[10]   A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand [J].
Chariyalertsak, S ;
Supparatpinyo, K ;
Sirisanthana, T ;
Nelson, KE .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) :277-284